Leiomyosarcoma metastatic

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Antimetabolite 1 substance
Phase III: 2 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Pharma Mar S.A. Commercial
    LURBINECTEDIN
    2022-502975-45-00 9 countries 2023 n=345
    Ended
  • Universitaet Muenster Academic
    TTF-NGR
    2024-516392-33-00 1 country 2021 n=126
    Recruiting

Phase II

1 trial
  • Italian Sarcoma Group Academic
    GEMCITABINE; TRABECTEDIN
    2024-513820-40-00 1 country 2021 n=100
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pharma Mar S.A. Commercial 1 Phase III 0
Italian Sarcoma Group Academic 1 Phase II 1
Universitaet Muenster Academic 1 Phase III 1
New trials by year
2021
2
2023
1
← All indication landscapes